Advertisement

Expert Point of View: Axel Le Cesne, MD


Advertisement
Get Permission


The evidence falls short, and further studies are needed with a longer follow-up, controlling for surgical expertise and including a control arm.
— Axel Le Cesne, MD

Tweet this quote

“The debate about perioperative chemotherapy in localized high-grade soft-tissue sarcoma is never-ending. Can this study resolve the debate?” asked formal discussant Axel Le Cesne, MD, of the Institute de Cancerologie Gustave-Roussy, Villejuif, France. “Surgery remains the standard of care for all patients with resectable soft-tissue sarcoma,” Dr. Le Cesne stated.

Previous studies evaluating adjuvant and neoadjuvant therapies in soft-tissue sarcoma have been limited by small numbers of patients, inadequate doses of chemotherapy, and short follow-up, and these studies did not take into account the histologic diversity of soft-tissue sarcoma, he said. “Despite this, neoadjuvant chemotherapy with anthracycline plus ifosfamide is the treatment of choice in marginally resectable soft-tissue sarcoma in referral centers, and the current findings of the study validate our routine practice in high-grade, high-risk patients with soft-tissue sarcoma,” he continued.

Further Studies Needed

However, Dr. Le Cesne did not endorse anthracycline/ifosfamide as a new standard of care, because in his view, the evidence falls short, and further studies are needed with a longer follow-up, controlling for surgical expertise and including a control arm without chemotherapy.

Dr. Le Cesne suggested that the suboptimal results in the histology-driven treatment arms could be due to the low number of cycles given in this setting to obtain a benefit (compared with those observed in advanced diseases) and by different biology between localized vs advanced soft-tissue sarcomas. However, he went as far as to say that the next European Society for Medical Oncology (ESMO) guidelines could incorporate neoadjuvant anthracycline/ifosfamide as an option to be discussed with patients who have a high-risk soft-tissue sarcoma of the extremities and/or trunk wall. ■

Disclosure: Dr. Le Cesne reported no potential conflicts of interest.


Related Articles

Neoadjuvant Chemotherapy in High-Risk Soft-Tissue Sarcoma: A New Standard?


Standard chemotherapy as neoadjuvant therapy is effective in these patients at high risk of relapse and is feasible in 90% of patients. These results may change the treatment of soft-tissue sarcoma of the extremities and trunk wall.
— Alessandro Gronchi, MD

Tweet this ...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.